Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer

Affiliations

¹ Department of Obstetrics and Gynaecology, Lokman Hekim University, Ankara, Türkiye. Electronic address: sutcuogluo@gmail.com.
² Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Türkiye.

Comment

Bengü Mutlu Sütcüoğlu et al. Lancet Oncol. 2023 Dec.

. 2023 Dec;24(12):e457.

doi: 10.1016/S1470-2045(23)00471-0.

¹ Department of Obstetrics and Gynaecology, Lokman Hekim University, Ankara, Türkiye. Electronic address: sutcuogluo@gmail.com.
² Department of Medical Oncology, Ankara Etlik City Hospital, Ankara, Türkiye.

No abstract available

Conflict of interest statement

We declare no competing interests.

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in advanced ovarian cancer - Authors' reply.
Aronson SL, Sonke GS, van Driel WJ. Aronson SL, et al. Lancet Oncol. 2023 Dec;24(12):e458. doi: 10.1016/S1470-2045(23)00588-0. Lancet Oncol. 2023. PMID: 38040000 No abstract available.

Cytoreductive surgery with or without hyperthermic intraperitoneal chemotherapy in patients with advanced ovarian cancer (OVHIPEC-1): final survival analysis of a randomised, controlled, phase 3 trial.
Aronson SL, Lopez-Yurda M, Koole SN, Schagen van Leeuwen JH, Schreuder HWR, Hermans RHM, de Hingh IHJT, van Gent MDJM, Arts HJG, van Ham MAPC, van Dam PA, Vuylsteke P, Aalbers AGJ, Verwaal VJ, Van de Vijver KK, Aaronson NK, Sonke GS, van Driel WJ. Aronson SL, et al. Lancet Oncol. 2023 Oct;24(10):1109-1118. doi: 10.1016/S1470-2045(23)00396-0. Epub 2023 Sep 11. Lancet Oncol. 2023. PMID: 37708912 Clinical Trial.